Tiziana Life Sciences is trading 8% higher at $1.03 after requesting FDA orphan drug designation for intranasal foralumab to treat multiple system atrophy.
- On September 30, 2026, the company announced its request; the FDA aims to review requests within 90 days.
- The designation has not yet been granted.
- Reuters reported cooler-than-expected inflation lifted U.S. stock-index futures. No verified trading-volume figure was supplied, so intraday activity cannot be assessed.